Logo image of ARCH.CA

ARCH BIOPARTNERS INC (ARCH.CA) Stock Price, Quote, News and Overview

TSX-V:ARCH - TSX Venture Exchange - CA03938C1041 - Common Stock - Currency: CAD

1.78  -0.06 (-3.26%)

ARCH.CA Quote, Performance and Key Statistics

ARCH BIOPARTNERS INC

TSX-V:ARCH (3/7/2025, 7:00:00 PM)

1.78

-0.06 (-3.26%)

Sector
GICS SectorHealth Care
GICS IndustryLife Sciences Tools & Services
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryLife Sciences Tools & Services
Statistics
52 Week High2.56
52 Week Low1.36
Market Cap116.75M
Shares65.59M
Float52.70M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)05-28 2025-05-28
IPO10-09 1996-10-09


ARCH.CA short term performance overview.The bars show the price performance of ARCH.CA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 5 -5 10 15

ARCH.CA long term performance overview.The bars show the price performance of ARCH.CA in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 -10 -20 -30 -40 -50

The current stock price of ARCH.CA is 1.78 CAD. In the past month the price decreased by -5.82%. In the past year, price increased by 1.71%.

ARCH BIOPARTNERS INC / ARCH Daily stock chart

ARCH.CA Competitors/Peers

The largest stocks on the Canadian markets in the "Life Sciences Tools & Services" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
IOT.CA INNOVOTECH INC N/A 7.46M

About ARCH.CA

Company Profile

ARCH logo image Arch Biopartners, Inc. is a portfolio-based biotechnology company, which engages in the development of technologies that have the potential to make a significant medical or commercial impact. The company is headquartered in Toronto, Ontario. The firm is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The firm is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The firm has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.

Company Info

ARCH BIOPARTNERS INC

545 King St W.

TORONTO ONTARIO M5V 1M1 CA

CEO: Richard Muruve

Employees: 0

Company Website: https://archbiopartners.com/

Investor Relations: http://www.archbiopartners.com/investor-hub/

Phone: 16474287031

ARCH BIOPARTNERS INC / ARCH.CA FAQ

What is the stock price of ARCH BIOPARTNERS INC today?

The current stock price of ARCH.CA is 1.78 CAD. The price decreased by -3.26% in the last trading session.


What is the ticker symbol for ARCH BIOPARTNERS INC stock?

The exchange symbol of ARCH BIOPARTNERS INC is ARCH and it is listed on the TSX Venture Exchange exchange.


On which exchange is ARCH.CA stock listed?

ARCH.CA stock is listed on the TSX Venture Exchange exchange.


What is the price forecast or stock price prediction for ARCH BIOPARTNERS INC stock?

7 analysts have analysed ARCH.CA and the average price target is 3.57 CAD. This implies a price increase of 100.56% is expected in the next year compared to the current price of 1.78. Check the ARCH BIOPARTNERS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is ARCH BIOPARTNERS INC worth?

ARCH BIOPARTNERS INC (ARCH.CA) has a market capitalization of 116.75M CAD. This makes ARCH.CA a Micro Cap stock.


How many employees does ARCH BIOPARTNERS INC have?

ARCH BIOPARTNERS INC (ARCH.CA) currently has 0 employees.


What are the support and resistance levels for ARCH BIOPARTNERS INC (ARCH.CA) stock?

ARCH BIOPARTNERS INC (ARCH.CA) has a support level at 1.77 and a resistance level at 1.85. Check the full technical report for a detailed analysis of ARCH.CA support and resistance levels.


Should I buy ARCH BIOPARTNERS INC (ARCH.CA) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does ARCH BIOPARTNERS INC (ARCH.CA) stock pay dividends?

ARCH.CA does not pay a dividend.


When does ARCH BIOPARTNERS INC (ARCH.CA) report earnings?

ARCH BIOPARTNERS INC (ARCH.CA) will report earnings on 2025-05-28.


What is the Price/Earnings (PE) ratio of ARCH BIOPARTNERS INC (ARCH.CA)?

ARCH BIOPARTNERS INC (ARCH.CA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.05).


ARCH.CA Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to ARCH.CA. When comparing the yearly performance of all stocks, ARCH.CA is a bad performer in the overall market: 69.4% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

ARCH.CA Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to ARCH.CA. ARCH.CA has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ARCH.CA Financial Highlights

Over the last trailing twelve months ARCH.CA reported a non-GAAP Earnings per Share(EPS) of -0.05. The EPS decreased by -134.8% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -399.14%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%-500%
Sales Q2Q%N/A
EPS 1Y (TTM)-134.8%
Revenue 1Y (TTM)105.62%

ARCH.CA Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 46% to ARCH.CA. The Buy consensus is the average rating of analysts ratings from 7 analysts.


Ownership
Inst OwnersN/A
Ins Owners18.35%
Short Float %N/A
Short RatioN/A
Analysts
Analysts45.71
Price Target3.57 (100.56%)
EPS Next Y-35.96%
Revenue Next YearN/A